Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Raymond C. Stevens
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 281
- Beta
- -1.51
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 22.89
Financials
Net Income
$-106.16MEBITDA
$-105.92MFree Cash Flow
$-120.07MEPS (diluted)
$-1.47Shares Outstanding (diluted)
72.65M+98.6%Operating Expenses
$118.63MCash & Debt
$1.34BReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-141.20M | $-2.40 |
| 2024 | $0.00 | $-122.53M | $-2.34 |
| 2023 | $0.00 | $-89.62M | $-2.43 |
| 2022 | $0.00 | $-51.32M | $-1.44 |
| 2021 | $0.00 | $-40.01M | $-1.20 |
| 2020 | $0.00 | $-15.90M | $-0.45 |
Valuation
GPCRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+3.45%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·6h ago·Neutral
…ucture Therapeutics to Participate in Upcoming Healthcare Investor Conferences SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in three upcoming healthcare conferences in September: 2026 Cantor Global Healthcare Conference Date: Thursday, September 10Forma…
View source ↗ - Newsseekingalpha.com·5d ago·Neutral
Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term Septerna, Inc. has surged >315% since May 2025, driven by its GPCR-focused drug discovery and a high-profile collaboration with Novo Nordisk. The SEPT partnership with NOVO targets GLP-1, GIP, and glucagon receptors, with $26.7m Q2 collaboration revenue and a new R&D program initiated. SEP-479, an oral small molecule for hypoparathyroidism, is a differentiated asset with a pivotal Q1 2027 data readout as a key catalys…
View source ↗
Earnings
Thu, Nov 5(in 2 months)
Consensus estimate $-0.32 per share
Typical surprise -12.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.49 vs $-0.39miss
- Thu, May 7$-0.35 vs $-0.39beat
- Thu, Feb 26$-0.49 vs $-0.35miss
- Thu, Nov 6$-0.37 vs $-0.36miss
- Wed, Aug 6$-0.36 vs $-0.28miss
- Thu, May 8$-0.27 vs $-0.24miss
Estimates and results for GPCR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GPCR officers and directors.
- Bought
- —
- Sold
- —
0 trades
34 trades
- Lin Xichensold
- Lin Xichensold
- Lin Xichensold
- Lin Xichensold
- Lin Xichensold
- Lin Xichensold
- Lin Xichensold
- Lin Xichensold
66 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.